TAGLN2 (transgelin 2) was first identified as a marker of differentiated smooth muscle. It is expressed in the adult smooth muscle cells and embryonic skeletal and cardiac tissues. Its function has not yet clear but it has been reported that TAGLN2 may plays a role in oncogenic function. Tumor suppressive microRNA (miRNA) gene regulates the TAGLN2 activity in head and neck squamous cell carcinoma (HNSCC).
Synonyms: Anti-SM22-alpha homolog; Anti-Transgelin-2
Storage: -20C
Application: Anti-TAGLN2 antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC